Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for his first injection of an experimental drug called ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

India's Zydus Lifesciences reported third-quarter profit above analysts' expectations on Wednesday, driven by strong demand for its generic drugs in its key U.S. market.

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

The USFDAs Office of Orphan Drug Products grants orphan status to support the development of medicines for the treatment of rare diseases that affect fewer than 200,000 people in the United States ...

Zydus Lifesciences: The pharmaceutical company announced the USFDA orphan drug designation to Usnoflast for the treatment ... gets approved. Laurus Labs: The US FDA issued a form 483 with one ...

Zydus, a leading, discovery-based, global pharmaceutical company announced that the US FDA has granted Orphan Drug Designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of ...

Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...

Zydus Lifesciences made headlines on Wednesday as the US health regulator bestowed Orphan Drug Designation upon Usnoflast, their developing treatment for amyotrophic lateral sclerosis (ALS). The US ...